{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:04:50Z","timestamp":1761674690592},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[1997,5,1]],"date-time":"1997-05-01T00:00:00Z","timestamp":862444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[1997,5]]},"DOI":"10.1006\/phrs.1997.0167","type":"journal-article","created":{"date-parts":[[2002,9,18]],"date-time":"2002-09-18T20:38:41Z","timestamp":1032381521000},"page":"481-485","source":"Crossref","is-referenced-by-count":25,"title":["COMPARATIVE EFFECTS ON INTRAOCULAR PRESSURE BETWEEN SYSTEMIC AND TOPICAL CARBONIC ANHYDRASE INHIBITORS: A CLINICAL MASKED, CROSS-OVER STUDY"],"prefix":"10.1006","volume":"35","author":[{"given":"M.","family":"CENTOFANTI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.L.","family":"MANNI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"NAPOLI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G.","family":"BUCCI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/phrs.1997.0167_FR970167RF1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0002-9394(55)90022-2","article-title":"The mechanism of the fall in intraocular pressure induced by the carbonic anidrase inhibitor Diamox","volume":"39","author":"Becker","year":"1955","journal-title":"Am J Ophthalmol"},{"key":"10.1006\/phrs.1997.0167_FR970167RF2","series-title":"Pharmacology of the Eye","article-title":"Carbonic anhydrase: pharmacology of the inhibitors and treatment of glaucoma","author":"Friedland","year":"1984"},{"key":"10.1006\/phrs.1997.0167_FR970167RF4","first-page":"113","article-title":"Topical carbonic anhydrase inhibitors","volume":"2","author":"Higginbotham","year":"1989","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1006\/phrs.1997.0167_FR970167RF5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/archopht.1992.01080160073033","article-title":"Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor","volume":"110","author":"Lippa","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"10.1006\/phrs.1997.0167_FR970167RF6","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archopht.1993.01090100051026","article-title":"Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor","volume":"111","author":"Wilkerson","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"10.1006\/phrs.1997.0167_FR970167RF7","doi-asserted-by":"crossref","first-page":"1143, 1143.","DOI":"10.1001\/archopht.1989.01070020209026","article-title":"MK-927: A topically effective carbonic anhydrase inhibitor in patients","volume":"107","author":"Bron","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"10.1006\/phrs.1997.0167_FR970167RF8","article-title":"Long term glaucoma treatment with MK-507, a topical carbonic anhydrase inhibitor","volume":"100(Suppl.):81","author":"Kitazawa","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1006\/phrs.1997.0167_FR970167RF9","doi-asserted-by":"crossref","unstructured":"Wistrand, PF, 1992, Distribution and function of carbonic anhydrase (CA) isoenzymes in the human eye: relevance for the design of topical CA inhibitors, Proceedings from the International Congress for Eye Research. Stresa, Italy","DOI":"10.1016\/0014-4835(92)90847-L"},{"key":"10.1006\/phrs.1997.0167_FR970167RF10","first-page":"930","article-title":"A study of thein vitro","volume":"34(suppl.)","author":"Sugrue","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1006\/phrs.1997.0167_FR970167RF11","first-page":"419","article-title":"Carbonic anhydrase isoenzymes CA I and CA II in the human eye","volume":"27","author":"Wistrand","year":"1986","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1006\/phrs.1997.0167_FR970167RF12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1267\/ahc.25.77","article-title":"The loci of carbonic anhydrase activity in the ciliary epithelium of the rabbit eye: electrophysiological study with isolated ciliary epithelial bilayer","volume":"25","author":"Murakami","year":"1992","journal-title":"Acta Histochem Cytochem"},{"key":"10.1006\/phrs.1997.0167_FR970167RF13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ddr.430100407","article-title":"Carbonic anhydrase: general perspective and advances in glaucoma research","volume":"10","author":"Maren","year":"1987","journal-title":"Drug Dev Res"},{"key":"10.1006\/phrs.1997.0167_FR970167RF14","series-title":"The glaucomas","article-title":"Carbonic anhydrase inhibitors","author":"Friedland","year":"1989"},{"key":"10.1006\/phrs.1997.0167_FR970167RF15","series-title":"Chandler and Grant's Glaucoma","article-title":"Carbonic anhydrase inhibitors. Systemic use","author":"Epstein","year":"1997"},{"key":"10.1006\/phrs.1997.0167_FR970167RF16","first-page":"445","article-title":"Binding of the carbonic anhydrase inhibitor MK-927 to ocular pigment","volume":"30(suppl.)","author":"Mallorga","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1006\/phrs.1997.0167_FR970167RF17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0002-9394(83)90017-X","article-title":"The effect of topically administered carbonic anhydrase inhibitors on aqueous humor dynamics in rabbits","volume":"95","author":"Stain","year":"1983","journal-title":"Am J Ophthalmol"},{"key":"10.1006\/phrs.1997.0167_FR970167RF18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/02713689008995202","article-title":"The effect of MK-927, a topical carbonic anhydrase inhibitor, an IOP in glaucomatous monkeys","volume":"9","author":"Wang","year":"1990","journal-title":"Curr Eye Res"},{"key":"10.1006\/phrs.1997.0167_FR970167RF19","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/archopht.1991.01080090123036","article-title":"MK-507 (L-671, 152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys","volume":"109","author":"Wang","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1006\/phrs.1997.0167_FR970167RF20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0002-9394(14)72009-4","article-title":"A six-week dose response study of the ocular hypotensive effect of Dorzolamide with a one-year extension","volume":"122","author":"Strahlman","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"10.1006\/phrs.1997.0167_FR970167RF21","first-page":"05.20, 05.20","article-title":"Stereoselective pharmacokinetics of MK-927, a novel topical carbonic anhydrase inhibitor following ocular administration","volume":"36(Suppl.)","author":"Biollaz","year":"1989","journal-title":"Eur J Clin Pharm"},{"key":"10.1006\/phrs.1997.0167_FR970167RF22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/clpt.1991.84","article-title":"Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects","volume":"49","author":"Buclin","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1006\/phrs.1997.0167_FR970167RF23","first-page":"51","article-title":"The effect of carbonic anhydrase inhibitors on urinary calcium and citrate","volume":"31","author":"Reeder","year":"1971","journal-title":"Trans Ophthalmol NZ"},{"key":"10.1006\/phrs.1997.0167_FR970167RF24","first-page":"1186","article-title":"The effect of topical ocular hypotensive carbonic anhydrase inhibitors on regional ocular blood flow in albino rabbits","volume":"32(suppl.)","author":"Sugrue","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661897901675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661897901675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T07:04:21Z","timestamp":1576479861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661897901675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1997,5]]}},"alternative-id":["S1043661897901675"],"URL":"https:\/\/doi.org\/10.1006\/phrs.1997.0167","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[1997,5]]}}}